{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-001074","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.193025+00:00","generated_at":"2026-06-27T18:37:34.975035+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenon Pharma receives $15M milestone from Neurocrine after FDA accepts pediatric epilepsy study expansion","bullets":["FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.","Xenon receives aggregate $15M: $6.75M cash plus $8.25M equity (258,986 shares at $31.855, a 15% premium to 30-day VWAP).","Full IND acceptance triggered per amendment to 2019 Collaboration Agreement with Neurocrine Biosciences.","Neurocrine's NBI-921352 is a selective Nav1.6 sodium channel inhibitor; two ongoing Phase 2 trials in epilepsy.","Xenon potential for future clinical, regulatory, and commercial milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-001074","json":"https://secwatch.observer/filing/0001564590-22-001074.json","markdown":"https://secwatch.observer/filing/0001564590-22-001074.md","text":"https://secwatch.observer/filing/0001564590-22-001074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/0001564590-22-001074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/xene-8k_20220111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:37:34.975035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}